A thermoplastic elastomer stopper that meets the desired material properties of a stopper for a syringe assembly is disclosed. The compression set of the thermoplastic elastomer stopper of the present disclosure is ≤50% when measured at 25% compression for 22 hrs at 70 degree C. The hardness of the thermoplastic elastomer stopper of the present disclosure is 40-70 Shore A. The viscosity of a thermoplastic elastomer stopper of the present disclosure is ≥70 Pa.Math.s at 1,000 s.sup.−1 shear rate, ≥12.0 Pa.Math.s at 10,000 s.sup.−1 shear rate, and ≥3.0 Pa.Math.s at 50,000 s.sup.−1 shear rate when measured using a capillary rheometer at 205 degree C. (Die: Roundhole 20 mm length/1 mm diameter/180 degree inlet, Piston: d=15 mm, and melting time=7 min). The present non-lubricated stopper exhibits the required functional performance of a lubricated stopper.

Modelling material which includes (a) at least one radically polymerizable monomer, (b) at least one initiator for the radical polymerization and (c) at least one inert component. The inert component (c) is soluble in the polymer formed by polymerization of the monomer (a), wherein the solubility of component (c) decreases as the temperature increases, with the result that a phase separation takes place above a particular temperature. The material is suitable in particular for the production of models of dental restorations for investment casting processes.

[Problem] To provide a softer resin material that can be highly filled with an oil and that has almost no seepage (bleed-out) of oil. Additionally, to provide a biological model that is easy to handle and that has a softness and mechanical properties closer to those of organs and a texture close to that of organs. [Solution] A resin composition containing 100 parts by mass of component (A), a hydrogenated block copolymer having an MFR (measured at a temperature of 230° C. and with a load of 2.16 kg) of 1 g/10 min or less; more than 1000 parts by mass and at most 2000 parts by mass of component (B), an oil; and at least 10 parts by mass and at most 120 parts by mass of component (C), a polyolefin resin having a specific surface area of 0.01 to 30 m.sup.2/g.

Bioactive coatings that are stabilized against inactivation by weathering are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate to form an active coating facilitating the removal of organic stains or organic material from food, insects, or the environment.

Bioactive polymers, including methods, compositions, and devices, for ophthalmic applications. The methods may include selecting a bioactive agent, conjugating the bioactive agent to a moiety to produce a bioactive monomer, and then performing a copolymerization reaction using as reactants the bioactive monomer and one or more other monomers each lacking the bioactive agent. The moiety of the bioactive monomer may react directly with at least one of the other monomers in the copolymerization reaction.

Oral treatment devices formed from wax-based compositions that are thermally stable when formed into a three-dimensional shape to a temperature of at least 45° C. and plastically deformable at room temperature (25° C.). The wax-based compositions include a wax fraction homogeneously blended with a polymer fraction. The wax fraction includes at least one wax. The polymer fraction includes at least one polymer selected such that, when the wax and polymer are homogeneously blended together, they yield a wax-based composition having the desired properties of thermal stability and plastic deformability. Oral treatment devices are dimensionally stable to a temperature of at least 40° C. without external support and can be plastically deformed in a user's mouth to become at least partially customized to the size and shape of user's unique dentition and/or an appliance in a user's mouth.

A medical polymer device comprising a biodegradable polymer is provided, wherein the biodegradable polymer has a crystallinity of about 10% to about 80%, and preferably from about 20% to about 60%, wherein the medical polymer device comprises a small molecule organic compound which diffuses into the biodegradable polymer, the small molecule organic compound has a molecular weight of from about 100 to about 1000 Daltons, preferably from about 150 to about 500 Daltons, and more preferably from about 150 to about 250 Daltons, and the small molecule organic compound is non-evaporating or low-evaporating. The present invention also provides a method for preparing a medical polymer device according to the present invention as well as a method for modifying a medical polymer device made from a biodegradable polymer.

The present invention relates to a photo-cross-linkable shape-memory polymer and a preparation method therefor. The shape-memory polymer according to one embodiment of the present invention comprises a photo-cross-linkable functional group, and thus a shape-memory polymer having a melting point suitable for a physiological or medical application device can be provided. Particularly, a method for preparing the shape-memory polymer, according to one embodiment of the present invention, uses a catalyst for inducing the simultaneous ring-opening polymerization of two monomers (CL, GMA) during synthesis of the shape-memory polymer, thereby enabling the synthesis time of the shape-memory polymer to be reduced, and shape-memory polymers having various melting points can be readily prepared by controlling the introduction amounts of CL and GMA.

Compositions comprise statistically random heteropolymers complexed with active proteins, and are formulated and used in stimuli-responsive materials and nanoreactors composed of proteins and synthetic materials.

This disclosure provides novel anionic amphiphilic β-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.